259 related articles for article (PubMed ID: 18691680)
1. Plasminogen activators are involved in the degradation of bone by osteoclasts.
Everts V; Daci E; Tigchelaar-Gutter W; Hoeben KA; Torrekens S; Carmeliet G; Beertsen W
Bone; 2008 Nov; 43(5):915-20. PubMed ID: 18691680
[TBL] [Abstract][Full Text] [Related]
2. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone.
Everts V; Korper W; Hoeben KA; Jansen ID; Bromme D; Cleutjens KB; Heeneman S; Peters C; Reinheckel T; Saftig P; Beertsen W
J Bone Miner Res; 2006 Sep; 21(9):1399-408. PubMed ID: 16939398
[TBL] [Abstract][Full Text] [Related]
3. Bone resorption and response to calcium-regulating hormones in the absence of tissue or urokinase plasminogen activator or of their type 1 inhibitor.
Leloup G; Lemoine P; Carmeliet P; Vaes G
J Bone Miner Res; 1996 Aug; 11(8):1146-57. PubMed ID: 8854251
[TBL] [Abstract][Full Text] [Related]
4. The role of the plasminogen system in bone resorption in vitro.
Daci E; Udagawa N; Martin TJ; Bouillon R; Carmeliet G
J Bone Miner Res; 1999 Jun; 14(6):946-52. PubMed ID: 10352103
[TBL] [Abstract][Full Text] [Related]
5. Increased bone formation in mice lacking plasminogen activators.
Daci E; Everts V; Torrekens S; Van Herck E; Tigchelaar-Gutterr W; Bouillon R; Carmeliet G
J Bone Miner Res; 2003 Jul; 18(7):1167-76. PubMed ID: 12854826
[TBL] [Abstract][Full Text] [Related]
6. Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone.
Everts V; Delaissé JM; Korper W; Beertsen W
J Bone Miner Res; 1998 Sep; 13(9):1420-30. PubMed ID: 9738514
[TBL] [Abstract][Full Text] [Related]
7. Family 2 cystatins inhibit osteoclast-mediated bone resorption in calvarial bone explants.
Brand HS; Lerner UH; Grubb A; Beertsen W; Nieuw Amerongen AV; Everts V
Bone; 2004 Sep; 35(3):689-96. PubMed ID: 15336605
[TBL] [Abstract][Full Text] [Related]
8. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases.
Everts V; Delaissé JM; Korper W; Niehof A; Vaes G; Beertsen W
J Cell Physiol; 1992 Feb; 150(2):221-31. PubMed ID: 1734028
[TBL] [Abstract][Full Text] [Related]
9. The relative contribution of cysteine proteinases and matrix metalloproteinases to the resorption process in osteoclasts derived from long bone and scapula.
Shorey S; Heersche JN; Manolson MF
Bone; 2004 Oct; 35(4):909-17. PubMed ID: 15454098
[TBL] [Abstract][Full Text] [Related]
10. Mice lacking tissue plasminogen activator and urokinase plasminogen activator genes show attenuated matrix metalloproteases activity after sciatic nerve crush.
Siconolfi LB; Seeds NW
J Neurosci Res; 2003 Nov; 74(3):430-4. PubMed ID: 14598319
[TBL] [Abstract][Full Text] [Related]
11. Different cysteine proteinases involved in bone resorption and osteoclast formation.
Brage M; Abrahamson M; Lindström V; Grubb A; Lerner UH
Calcif Tissue Int; 2005 Jun; 76(6):439-47. PubMed ID: 15906014
[TBL] [Abstract][Full Text] [Related]
12. Tissue and urokinase plasminogen activators in bone tissue and their regulation by parathyroid hormone.
Leloup G; Peeters-Joris C; Delaisse JM; Opdenakker G; Vaes G
J Bone Miner Res; 1991 Oct; 6(10):1081-90. PubMed ID: 1796756
[TBL] [Abstract][Full Text] [Related]
13. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
14. The effect of transforming growth factor beta on the plasminogen activator activity of normal human osteoblast-like cells and a human osteosarcoma cell line MG-63.
Fawthrop FW; Oyajobi BO; Bunning RA; Russell RG
J Bone Miner Res; 1992 Dec; 7(12):1363-71. PubMed ID: 1481722
[TBL] [Abstract][Full Text] [Related]
15. The effects of serine proteinase inhibitors on bone resorption in vitro.
Tumber A; Papaioannou S; Breckon J; Meikle MC; Reynolds JJ; Hill PA
J Endocrinol; 2003 Sep; 178(3):437-47. PubMed ID: 12967336
[TBL] [Abstract][Full Text] [Related]
16. A scrutiny of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells.
Andersen TL; del Carmen Ovejero M; Kirkegaard T; Lenhard T; Foged NT; Delaissé JM
Bone; 2004 Nov; 35(5):1107-19. PubMed ID: 15542036
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
18. Degradation of the organic phase of bone by osteoclasts: a secondary role for lysosomal acidification.
Henriksen K; Sørensen MG; Nielsen RH; Gram J; Schaller S; Dziegiel MH; Everts V; Bollerslev J; Karsdal MA
J Bone Miner Res; 2006 Jan; 21(1):58-66. PubMed ID: 16355274
[TBL] [Abstract][Full Text] [Related]
19. Identification of plasminogen activator in osteoclasts.
Grills BL; Gallagher JA; Allan EH; Yumita S; Martin TJ
J Bone Miner Res; 1990 May; 5(5):499-505. PubMed ID: 2114731
[TBL] [Abstract][Full Text] [Related]
20. Cystatin B as an intracellular modulator of bone resorption.
Laitala-Leinonen T; Rinne R; Saukko P; Väänänen HK; Rinne A
Matrix Biol; 2006 Apr; 25(3):149-57. PubMed ID: 16321512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
